You are here: Industry Insights > ASC41

News List

Gannex Announces the First Cohort Dosed in a U.S. Clinical Study with THR-β Agonist ASC41 prnasia
April 15, 2021
Gannex, a wholly owned company of Ascletis Pharma Inc., fully dedicated to the R&D and commercialization of new drugs in the field of non-alcoholic steatohepatitis (NASH), announces the dosing of the first cohort in the U.S. Phase I clinical study of ...
Gannex Announces Positive Clinical Results in Overweight and Obese Subjects for Its THR-β Agonist ASC41 prnasia
February 22, 2021
Gannex announces the positive clinical results in overweight and obese subjects for ASC41, a liver-targeted prodrug. The active metabolite of ASC41 is a selective thyroid hormone receptor beta (THR-β) agonist.
Gannex Announces Positive Phase I Clinical Results on Its THR-β Agonist ASC41 prnasia
January 12, 2021
Gannex, a wholly owned company of Ascletis Pharma Inc. and fully dedicated to the R&D and commercialization of new drugs in the field of non-alcoholic steatohepatitis (NASH), today announces the positive phase I clinical results of ASC41 oral tablet ...
Overweight and Obese Subjects Dosed with ASC41 Tablets in a Phase Ib Trial prnasia
December 22, 2020
Gannex announces today dosing of overweight and obese subjects in a Phase Ib trial of ASC41, an oral tablet, liver-targeted prodrug and its active moiety (ASC41-A), a selective thyroid hormone receptor beta (THR-β) agonist.
Gannex receives US IND Approval for NASH drug candidate, an FXR agonist expresspharma
October 14, 2020
In two NASH animal models, ASC42 demonstrated significant improvements in liver steatosis, inflammation and fibrosis.